Legend Capital took part in a $46.3m series B-plus round for enzyme product developer Yeasen Biotechnology two months after the latter closed its series B round.
China-based life sciences enzyme product developer Yeasen Biotechnology has raised RMB300m ($46.3m) in a series B-plus round featuring Legend Capital, the venture capital firm established by conglomerate Legend Holdings, DealStreetAsia reported yesterday.
Alternative asset manager Citic Private Equity Funds Management led the round, which was also backed by HM Capital, Haiwang Capital, Huasai Fund and Hongkou Kangrui Investment.
Founded in 2014, Yeasen provides a range of enzyme and antibody products for the life sciences sector. It offers more than 3,000…
